Logo.jpg
Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
September 17, 2021 09:00 ET | Celsion CORP
 Expands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J. and HAINAN, China, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
Logo.jpg
Celsion Appoints Christine A. Pellizzari to its Board of Directors
June 09, 2021 08:00 ET | Celsion CORP
Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J., June 09, 2021 (GLOBE...
logo.png
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
May 25, 2021 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
logo.png
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
May 13, 2021 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...
logo.png
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
May 11, 2021 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Logo.jpg
Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses
May 11, 2021 08:00 ET | Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J., May 11, 2021 ...
logo.png
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
April 20, 2021 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity...
logo.png
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
October 08, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Company is restructuring with the goal of extending cash runway to mid-2022Workforce to be reduced by 54%Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline...